Replimune Group, Inc. (REPL) Investor Relations Documents

Replimune Group, Inc. (REPL) investor relations documents from the company's IR site: 1 presentation, 15 press releases; latest deck 2026-05-30. Read in-app with summaries. First-party data.

RP1+ Nivolumab in Patients with Anti-PD-1-Failed Melanoma from the IGNYTE trial at ASCO 2026 — The 3-year IGNYTE trial analysis of RP1 plus nivolumab in anti–PD-1–failed melanoma shows a median overall survival of 32.9 months and a 47.8% 3-year OS rate.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-19Press releaseReplimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-08-14Press releaseReplimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update
2026-08-10Press releaseReplimune Announces Pricing of $150 Million Underwritten Offering
2026-08-06Press releaseReplimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutan
2026-07-30Press releaseReplimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 i
2026-06-29Press releaseReplimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update
2026-06-26Press releaseReplimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma
2026-05-31Press releaseReplimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 Ameri
2026-05-30Press releaseReplimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the
2026-05-30PresentationRP1+ Nivolumab in Patients with Anti-PD-1-Failed Melanoma from the IGNYTE trial at ASCO 2026
2026-05-29Press releaseReplimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA
2026-04-27Press releaseReplimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
2026-04-10Press releaseReplimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Adva
2026-03-02Press releaseReplimune to Present at Two Upcoming Investor Conferences
2026-02-03Press releaseReplimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
Press releaseReplimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update

REPL overview · REPL earnings · REPL financials · REPL KPIs · REPL ownership · REPL peers · REPL filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.